Drug Trial Radar · NCT06065748
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,050
Planned (sponsor's estimate)
Start
Dec 11, 2023
Primary completion
Apr 20, 2028
Study completion Feb 12, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Conditions
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions
GiredestrantDrug
Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
FulvestrantDrug
Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
AbemaciclibDrug
If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
PalbociclibDrug
If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
RibociclibDrug
If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
LHRH AgonistDrug
Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
FoundationOne Liquid CDx Assay (F1LCDx)Diagnostic test
F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) in the ESR1 mutation (ESR1m) SubgroupTime frame: From randomization to first occurrence of progressive disease (PD) or death (up to 5 years)
- PFS in the Full Analysis Set (FAS) PopulationTime frame: From randomization to first occurrence of PD or death (up to 5 years)
Locations
311 sites in 37 countries. Site status is shown where the registry gives one.
Southern Cancer Center
Daphne, Alabama
Marin Cancer Care Inc
Greenbrae, California
Kaiser Permanente - Harbor City
Harbor City, California
Oncura Health
Los Angeles, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente
Torrance, California
Rocky Mountain Cancer Centers
Littleton, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
MedStar Washington Hosp Center
Washington D.C., District of Columbia
AdventHealth Altamonte
Altamonte Springs, Florida
Florida Cancer Specialists - Broadway
Fort Myers, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Florida Cancer Specialists - North;725 6th Ave South (St. Petersburg)
St. Petersburg, Florida
Comprehensive Hematology Oncology
St. Petersburg, Florida
Florida Cancer Specialists - EAST - SCRI - PPDS
West Palm Beach, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Baptist Health Louisville
Louisville, Kentucky
New England Cancer Specialists
Scarborough, Maine
Maryland Oncology Hematology
Annapolis, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
HCA Midwest Division
Kansas City, Missouri
Oncology Hematology West - Grand Island
Grand Island, Nebraska
Oncology Hematology West - Legacy
Omaha, Nebraska
Astera Cancer Care East Brunswick
East Brunswick, New Jersey
Duke Women Cancer Care
Raleigh, North Carolina
Asante Rogue Regional Medical Center
Medford, Oregon
Alliance Cancer Specialists
Bensalem, Pennsylvania
Ann B. Barshinger Cancer Institute
Lancaster, Pennsylvania
Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit
Philadelphia, Pennsylvania
Brown University Health
Providence, Rhode Island
Avera Cancer Institute
Sioux Falls, South Dakota
West Cancer Center
Germantown, Tennessee
SCRI Oncology Partners
Nashville, Tennessee
Texas Oncology Cancer Center
Austin, Texas
Texas Oncology - DFW
Irving, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
Virginia Commonwealth University - Massey Cancer Center
Richmond, Virginia
Northwest Medical Specialties
Tacoma, Washington
West Virginia University Hospitals Inc
Morgantown, West Virginia
Showing 40 of 311 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.